Master Rollover Protocol for Continued Safety Assessment of Study Drug
ConditionCancer
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18+
SponsorEli Lilly and Company
About this trial
This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.
Disqualifiers
Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
Trial design
Treatments tested in this trial
LY2503029
DrugAdministered orally.
LY3023414
DrugAdministered orally.
LY3838915
DrugAdministered orally.
LY3847429
DrugAdministered orally.
Treatment groups
No treatment groups listed
Trial outcomes
This trial has no outcomes listed.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov